Lipoprotein(a) in atherosclerotic cardiovascular disease and proprotein convertase subtilisin/kexin-type 9 inhibitors
Clinica Chimica Acta · 2025
DOI: 10.1016/j.cca.2024.119982 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinica Chimica Acta, 2025. Verfasst von Ping-An Lian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Atherosclerosis, Lipoprotein(a), PCSK9 Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 168 Literaturangaben. Gefördert von: Hunan Provincial Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
High plasma lipoprotein(a) (Lp(a)) levels increase the cardiovascular risk in populations with atherosclerotic cardiovascular disease (ASCVD). Apolipoprotein (a) [apo(a)], a unique protein component of Lp(a), plays an important role in the pathogenesis of atherosclerosis. Statins, the primary medication in managing ASCVD, lower low-density lipoprotein cholesterol (LDL-C) but concurrently elevate plasma Lp(a) levels, contributing to an increased residual cardiovascular risk. In turn, proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors, a novel class of LDL-C lowering drugs, effectively reduce plasma Lp(a) levels, which is believed to decrease residual cardiovascular risk. However, the mechanism by which PCSK9 inhibitors reduce Lp(a) levels remains unknown. In addition, there are some clinical limitations of PCSK9 inhibitors. Here, we systematically review the past, present, and prospects of studies pertaining to Lp(a), PCSK9 inhibitors, and ASCVD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Stomatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Cardiovascular Medicine, Guilin Hospital of The Second Xiangya Hospital, Central South…
- Department of Stomatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Stomatology, Guilin Hospital of The Second Xiangya Hospital, Central South University, Guilin, Chin…
Förderung
- Hunan Provincial Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Lian, P. A., Zhu, W. Q., Zhao, W. X., Huang, P. P., Ran, J. L., Tang, Y. X., Huang, X. S., & Li, R. (2025). Lipoprotein(a) in atherosclerotic cardiovascular disease and proprotein convertase subtilisin/kexin-type 9 inhibitors. Clinica Chimica Acta. https://doi.org/10.1016/j.cca.2024.119982
Vancouver
Lian PA, Zhu WQ, Zhao WX, Huang PP, Ran JL, Tang YX, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and proprotein convertase subtilisin/kexin-type 9 inhibitors. Clinica Chimica Acta. 2025. doi:10.1016/j.cca.2024.119982
BibTeX
@article{Lian2025,
author = {Lian, Ping-An and Zhu, Wen-Qiang and Zhao, Wei-Xin and Huang, Piao-Piao and Ran, Juan-Li and Tang, Ya-Xin and Huang, Xian-Sheng and Li, Rong},
title = {Lipoprotein(a) in atherosclerotic cardiovascular disease and proprotein convertase subtilisin/kexin-type 9 inhibitors},
journal = {Clinica Chimica Acta},
year = {2025},
doi = {10.1016/j.cca.2024.119982}
}
EUVIMED